本帖最后由 老马 于 2013-3-13 13:43 编辑
7 A: L2 e4 t9 S6 y) t
2 a5 ^) T9 L# }/ w健择(吉西他滨)+顺铂+阿瓦斯汀
" F/ w6 t: a+ o9 T1 | Gemzar +Cisplatin + Avastin( ]% ]. E: O; b8 X4 x2 g8 {
http://annonc.oxfordjournals.org/content/21/9/1804.full* S0 p: k( C, } V$ y0 q$ v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) & a r d4 ?1 f& x0 _5 a9 t& A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; c4 ]; c3 ]3 H0 w( }) HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 G9 _+ N0 ~8 Y; ]" u
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 878)
1 c' o/ r$ y. h8 H# O/ ]
华为网盘附件:
9 Y. |: V& O$ J( s【华为网盘】ava.JPG
* V k: N; j1 R# Z2 `: [: x |